Serum mesothelin in epithelial ovarian carcinoma: A new screening marker and prognostic factor

Anticancer Research

Volumn 26, Issue 6 C, 2006, Pages 4721-4728

  Huang, Chia Yen ^a   Cheng, Wen Fang ^a   Lee, Chien Nan ^a   Su, Yi Ning ^a   Chien, Shu Chin ^a   Tzeng, Yu Lin ^a   Hsieh, Chang Yao ^a   Chen, Chi An ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Epithelial ovarian carcinoma; Mesothelin; Survival; Tumor marker

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; MESOTHELIN;

ADULT; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER SCREENING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTADENOMA; CYTOREDUCTIVE SURGERY; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVARY TUMOR; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ADULT; CA-125 ANTIGEN; CYSTADENOMA; EPITHELIAL CELLS; FEMALE; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREOPERATIVE CARE; PROGNOSIS;

EID: 33846018044     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Pfleiderer A: Diagnosis and staging of ovarian cancer. J Cancer Res Clin Oncol 107: 81-88, 1984.
2. Gonzalez-Diego P, Lopez-Abente G, Pollan M, and Ruiz M: Time trends in ovarian cancer mortality in Europe (1955-1993): effect of age, birth cohort and period of death. Eur J Cancer 36: 1816-1824, 2000.
3. Tarone RE and Chu KC: Age-period-cohort analyses of breast, ovarian-, endometrial- and cervical-cancer mortality rates for Caucasian women in the USA. J Epidemiol Biostat 5: 221-231, 2000.
4. Parkin DM, Pisani P and Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54: 594-606, 1993.
5. Beard CM, Hartmann LC, Atkinson EJ, O'Brien PC, Malkasian GD, Keeney GL and Melton III LJ: The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991. Ann Epidemiol 10: 14-23, 2000.
6. Boyle P, Maisonneuve P and Autier P: Update on cancer control in women. Int J Gynaecol Obstet 70: 263-303, 2000.
7. Gonzalez-Diego P, Lopez-Abente G, Pollan M and Ruiz M: Time trends in ovarian cancer mortality in Europe (1955-1993). Effect of age, birth cohort and period of death. Eur J Cancer 36: 1816-1824, 2000.
8. Rustin GJ: Tumour markers for ovarian cancer. Eur J Cancer 28: 2-3, 1992.
9. Sorbe B, Frankendal B and Veress B: Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol 59: 576-582, 1992.
10. Hacker NF, Berek JS, Lagasse LD, Nieberg RK and Elashoff RM: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61: 413-420, 1983.
11. Malkasian GD Jr, Melton LJ 3rd and O'Brien PC and Greene MH: Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 149: 274-284, 1984.
12. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N and Boyes DA: Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 65: 264-270, 1985.
13. Jacobs I and Bast RC Jr: The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 4: 1-12, 1989.
14. Mazurek A, Niklinski J, Laudanski T and Pluygers E: Clinical tumour markers in ovarian cancer. Eur J Cancer Prev 7: 23-35, 1998.
15. Berek JS and Bast RC Jr: Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 76: 2092-2096, 1995.
16. Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F, Casaldi V, Wappner G, Abbolito MR, Greiner JW et al: CA 72-4 serum marker - a new tool in the management of carcinoma patients. Cancer Invest 13: 227-238, 1995.
17. Pannek J and Partin AW: The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Semin Urol Oncol 16: 100-105, 1998.
18. Hunerbein M: The value of tumor markers in colorectal cancer. Recent Results Cancer Res 146: 48-55, 1998.
19. Posner MR and Mayer RJ: The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin North Am 8: 533-553, 1994.
20. Rubach M, Szymendera JJ, Kaminska J and Kowalska M: Serum CA 15.3, CEA and ESR patterns in breast cancer. Int J Biol Markers 12: 168-173, 1997.
21. Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93: 136-140, 1996.
22. Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, and Ochi N: A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 269: 805-808, 1994.
23. Chang K, Pastan I and Willingham MC: Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50: 373-381, 1992.
24. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ and Morin PJ: Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60: 6281-6287, 2000.
25. Sobin LH WC: UICC TNM Classification of Malignant Tumors, Fifth Edition, New York, New York, Wiley-Liss, 1997.
26. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE and Hellstrom I: Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 96: 11531-11536, 1999.
27. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Rice CM, Ling M and Wu TC: Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol 166: 6218-6226, 2001.
28. Bera TK and Pastan I: Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 20: 2902-2906, 2000.
29. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998.
30. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS and Cramer DW: Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 93: 1458-1464, 2001.
31. Wang K, Gan L, Jeffery E, Gayle M, Gown AM, Skelly M, Nelson PS, Ng WV, Schummer M, Hood L and Mulligan J: Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 229: 101-108, 1999.
32. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB and Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: 1331-1337, 1981.
33. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, eavitt T, Griffiths CT, Parker L, Zurawski VR Jr and Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 509: 883-887, 1983.
34. Meyer T and Rustin GJ: Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 82: 1535-1538, 2000.
35. Chen CA, Cheng WF, Lee CN, Chen TM, Kung CC, Hsieh FJ and Hsieh CY: Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol 74: 235-240, 1999.
36. Tuxen MK, Soletormos G and Dombernowsky P: Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 21: 215-245, 1995.
37. Mills GB, Bast RC Jr and Srivastava S: Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst 93: 1437-1439, 2001.
38. Robertson DM, Stephenson T, Pruysers E, Burger HG, McCloud P, Tsigos A, Groome N, Mamers P, McNeilage J, Jobling T and Healy D: Inhibins/activins as diagnostic markers for ovarian cancer. Mol Cell Endocrinol 191: 97-103, 2002.
39. Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T and Cristofani R: Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 58: 42-47, 1995.
40. Tate S, Hirai Y, Takeshima N and Hasumi K: CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol 96: 143-149, 2005.
41. Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ and Pastan I: Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother 23: 473-479, 2000.
42. Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC and Pastan I: Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 8: 3520-3526, 2002.
43. Sato N, Fukushima N, Maitra A, Iacobuzio-Donahue CA, van Heek NT, Cameron JL, Yeo CJ, Hruban RH and Goggins M: Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol 164: 903-914, 2004.
44. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M and Hruban RH: Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characteri-zation and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63: 8614-8622, 2003.
45. Ryu B, Jones J, Blades NJ, Parmigiani G, Hollingsworth MA, Hruban RH and Kern SE: Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 62: 819-826, 2002.
46. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE and Hruban RH: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7: 3862-2868, 2001.
47. Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, Schulick RD, Yeo CJ, Rahman A, Hinkle DA, Hruban RH and Argani P: Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 35: 357-366, 2004.
48. Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, Segal NH, Maki RG, Socci ND, DeMatteo RP and Besmer P: Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10: 3282-3290, 2004.
49. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE and Hellstrom I: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362: 1612-1616, 2003.
50. Frierson HF Jr, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, Cathro H and Hampton GM: Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 34: 605-609, 2003.